Skip to main content
Psych Congress  

Weight Gain and Treatment Interruptions With Second-Generation Oral Antipsychotics: Analysis of Real-World Data Among Patients With Schizophrenia or Bipolar I Disorder


Michael Doane, PhD-Associate Director, Health Economics and Outcomes Research, Alkermes, Inc.; Leona Bessonova, PhD-Senior Director, Health Economics and Outcomes Research, Alkermes, Inc.; Kathleen Mortimer, ScD, MPH-Director of Epidemiology, OM1, Inc.; Harry Cheng, MA, MPH-Senior Statistical Analyst, OM1, Inc.; Gregory Donadio, MA-Statistical Scientist, OM1, Inc.; Thomas Brecht, MS-Senior Statistical Analyst, OM1, Inc.; Amy O’Sullivan, PhD-Vice President, Health Economics & Outcomes Research, Alkermes, Inc.; Hannah Cummings, PhD-Medical Director, Medical Affairs Strategy, Alkermes, Inc.; David McDonnell, MD-Executive Medical Director, Clinical Science, Alkermes Pharma Ireland Ltd.; Jonathan Meyer, MD-Clinical Professor of Psychiatry, Department of Psychiatry, University of California, San Diego School of Medicine

Alkermes, Inc.

Among patients with schizophrenia (SZ) and bipolar I disorder (BD-I) treated with second-generation antipsychotics (SGAs), clinically-significant weight gain (CSWG) and treatment interruptions (TIs) are challenges that may result in morbidity/mortality.  

CSWG and TIs were assessed among patients who initiated oral SGAs of moderate-to-high weight gain risk (no exposure to index SGAs/first-generation antipsychotics for ≥12 months) using medical records/claims (OM1 Data Cloud; January 2013-February 2020).  Outcomes included CSWG (≥7% increase in baseline weight) and TIs (switches [to SGAs of low weight gain risk/long-acting injectables] or discontinuations [no SGAs for >30 days]).  Descriptive analyses included proportions of patients with CSWG and TIs, and median time to these outcomes.

Approximately three-quarters of patients were overweight/obese at baseline (SZ: N=8,174; BD-I: N=9,142).  Within 3 months of SGA initiation, 12% of all patients experienced CSWG.  For patients on treatment with index SGAs for >6 months (SZ: 29%; BD-I: 27%), 28% (SZ) and 30% (BD-I) experienced CSWG during follow-up.  Median time to CSWG was 14 weeks.  CSWG results were numerically similar among patients with SZ and BD-I.

Over 96% of patients had TIs during follow-up (median time of 12 [SZ] and 13 [BD-I] weeks).  Among patients with CSWG and subsequent TIs and weight measurements, 74% did not return to baseline weight after interrupting treatment; the remainder returned to baseline weight with median times of 38 (SZ) and 39 (BD-I) weeks.  Results suggest that most patients with CSWG do not return to baseline weight after stopping treatment with oral SGAs of moderate-to-high weight gain risk.

Back to Top